Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
AAD 2026: Remibrutinib Shows Early CSU Symptom Relief
March 2026
Remibrutinib improved itch and hive severity within 12 hours in chronic spontaneous urticaria in Phase III analysis.
Read more
27 Mar 2026
AAD 2026: Remibrutinib Shows Early CSU Symptom Relief
Remibrutinib improved itch and hive severity within 12 hours in chronic spontaneous urticaria in Phase III analysis.
26 Mar 2026
Botulinum Toxin Type A Linked to Serum Sickness
Serum sickness after botulinum toxin type A may signal a rare delayed systemic immune reaction. Read more.
23 Mar 2026
Microneedle Patches May Improve Hyperpigmentation Treatment
Microneedle patches may improve hyperpigmentation treatment by enhancing skin delivery, efficacy, and tolerability of active agents.
19 Mar 2026
Upper Face Rejuvenation Improves with Onabotulinum Toxin A Combination
Definisse KP1 eye contour cream may enhance eye rejuvenation when combined with onabotulinum toxin A. Read more.
16 Mar 2026
Fractional CO2 Laser Versus Microneedling for Acne Scars
Fractional CO2 laser improved post-acne scars more than microneedling radiofrequency, but with greater pain and downtime.
12 Mar 2026
Delgocitinib Cream Improves Quality of Life in Hand Eczema
Delgocitinib cream significantly improved quality of life in adults with moderate to severe Chronic Hand Eczema (CHE) in pooled phase III trial data.
9 Mar 2026
Abrocitinib Shows Long-Term Success in Atopic Dermatitis
Abrocitinib appears durable and well tolerated in patients with moderate-to-severe atopic dermatitis (AD), also known as eczema, according to a 2-year retrospective real-world study.
4 Mar 2026
Second-Line Pazopanib Yields Positive Responses in Angiosarcomas
Pazopanib shows activity and manageable safety in paclitaxel-pretreated cutaneous angiosarcoma, offering a potential second-line therapy option.
Loading posts...
1
2
3
…
23
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View